Kiran Klaus Patel

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 501 citations · Full text

Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Georgina V. Long, Jeffrey S. Weber, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2016 · 284 citations

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i>^V600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Douglas B. Johnson, Keith T. Flaherty, Jeffrey S. Weber et al. · Journal of Clinical Oncology · 2014 · 208 citations · Full text

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

J Cassidy, J.-Y. Douillard, C.J. Twelves et al. · British Journal of Cancer · 2006 · 124 citations · Full text